Substituted Aromatic Sulfur Compounds and Methods of Their Use
AssigneesCephalon, Inc., University of Utah Research Foundation, University of Hawaii
InventorsBruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
Life of this patent
Estimating the term…
Abstract
Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
Claims51
A compound of formula I, or a pharmaceutically acceptable salt form thereof,
- wherein A is at the 3- or 4-position of the phenyl ring;
- and
- A is
- R1 and R2 are each independently substituted or unsubstituted alkyl or R1 and R2, together with the carbon atom to which they are attached, form a three- to seven-membered substituted or unsubstituted cycloalkyl ring
- R3 is —OH, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkylalkyl, or
- —NR4R5;
- R4 and R5 are each independently H, substituted or unsubstituted alkyl, substituted or unsubstituted alkyene oxide, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, —COOalkyl, —COalkyl, —COcycloalkyl, —NHCOalkyl, —NHCOaryl, or —NHCOcycloalkyl;
- or R4 and R5, together with the atoms through which they are attached, form a substituted or unsubstituted heterocycloalkyl ring;
- and
- R6 is substituted or unsubstituted heteroaryl.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating or reducing the risk of peritoneal carcinomatosis in a patient that has had an intra-abdominal cancer removed, said method comprising administering to said patient a therapeutically effective amount of a compound selected from:
- (E)-3-(4-tert-Butyl-benzenesulfonyl)-acrylamide;
- 1-tert-butyl-4-[((E)-prop-1-ene)-1-sulfonyl]-benzene;
- 1-tert-butyl-4-((E)-2-phenyl-ethenesulfonyl)-benzene;
- 1-tert-butyl-4-(1-phenyl-ethenesulfonyl)-benzene;
- (E)-3-(4-tert-Butyl-benzenesulfonyl)-acrylic acid ethyl ester;
- (E)-3-(4-tert-butyl-phenylsulfanyl)-acrylonitrile;
- [2-tert-Butyl-4-((E)-2-cyano-ethenesulfonyl)-phenoxy]-acetic acid;
- 2-[2-tert-Butyl-4-((E)-2-cyano-ethenesulfonyl)-phenoxy]-N-cyclohexyl-acetamide;
- 2-[2-tert-Butyl-4-((E)-2-cyano-ethenesulfonyl)-phenoxy]-N-(4-fluoro-benzyl)-acetamide;
- 2-[2-tert-Butyl-4-((E)-2-cyano-ethenesulfonyl)-phenoxy]-N-(3-methoxy-phenyl)-acetamide;
- 2-[2-tert-Butyl-4-((E)-2-cyano-ethenesulfonyl)-phenoxy]-N-(2-hydroxy-5-methyl-phenyl)-acetamide;
- (E)-3-[3-tert-Butyl-4-(5-methyl-benzoxazol-2-ylmethoxy)-benzenesulfonyl]-acrylonitrile;
- 4-[4-((E)-2-Cyano-ethenesulfonyl)-phenyl]-tetrahydro-pyran-4-carboxylic acid;
- 4-[4-((E)-2-Cyano-ethenesulfonyl)-phenyl]-tetrahydro-pyran-4-carboxylic acid cyclohexylamide;
- 4-[4-((E)-2-Cyano-ethenesulfonyl)-phenyl]-tetrahydro-pyran-4-carboxylic acid phenylamide;
- or
- 4-[4-((E)-2-Cyano-ethenesulfonyl)-phenyl]-tetrahydro-pyran-4-carboxylic acid 4-chloro-benzylamide;
- or a pharmaceutically acceptable salt form thereof.
Dependencies are inferred from the claim text.